Byline: Market Analysis & Forecast ACADIA Pharmaceuticals isn’t screaming for attention—but based on recent CEO commentary and financial results, it might not need to. The tone from leadership has been consistent: 👉 strong execution, expanding commercial momentum, and confidence in long-term growth driven by its CNS (central nervous system) portfolio. And unlike many biotech peers, ACADIA is no longer just a pipeline story—it’s actually making money . The News: From Pipeline Story to Profit Machine Recent CEO messaging (from earnings and investor commentary) highlights three key themes: Continued commercial strength of NUPLAZID Rapid uptake of DAYBUE (Rett syndrome therapy) Confidence in scaling revenue toward multi-billion levels And the numbers back it up: 2025 revenue: ~$1.08B 2026 guidance: $1.22B–$1.28B Net income (2025): $391M Cash: ~$820M This is a major shift. 👉 ACADIA has crossed the line from speculative biotech → profitable commerc...